Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
about
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTTargeting the innate immune system as immunotherapy for acute myeloid leukemiaMHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trialMHC haplotype matching for unrelated hematopoietic cell transplantation.Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trialOptimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrAllogeneic hematopoietic cell transplantation: the state of the artNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioOutcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioningComparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of ageEstablishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioningFactors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitutionNon-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemiaTreatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamideTreatment of chronic graft-versus-host disease: Past, present and future.Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignanciesThe impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationReduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cellsDonor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survivalFactors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.Mesenchymal stromal cells: a new tool against graft-versus-host disease?Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamideNonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the AGraft-vs-host disease after non-myeloablative hematopoietic cell transplantation.T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulinReduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
P2860
Q24685958-3B13EC60-A0EC-4021-8960-C1ABE5B08FA5Q27015876-D8C275A4-83DE-4465-80B1-C33E064495C6Q30412320-56281E3B-BB4C-4AE1-AABD-A9DE80D5D6E1Q30543777-A380DCE4-14C8-4FE2-B973-9175B16AC63AQ33279672-7A8FCB18-71E5-4A6C-B84A-1CA5B131760AQ33386036-745A541A-8635-43B3-B95D-754249994421Q33653406-0A531BBF-A3EC-4E1B-800B-4CEB8241B270Q33771667-2FC4CB2C-A851-4CDC-83CD-DED5D52816D8Q33841438-D8604FDF-FE25-4F72-AEB7-B546F7942E18Q34044024-081F7984-095E-4AC5-9ADE-72AEBB0C3E9CQ34145155-415ECF85-F7E7-42ED-AF11-401DC828B5CEQ34202277-DD9743E5-0913-456A-BD5F-D31BE4ED32AEQ34240410-48721EE1-BC52-481D-B823-9C5C62675FCBQ34272554-78CAB8B0-CC7E-47E6-AC73-B20D3A91CA58Q34325244-74E35AFA-DCE0-4D1E-97BF-8F3385F9940EQ34360641-043C6C7A-2699-4DCB-9195-ED1E3080E06AQ34543056-0ED11B6A-6938-46B1-9FC2-F6582C4F3AFEQ34557219-06080E68-5A86-4A9A-8C46-A0D795E83F4BQ34598248-E67A7290-B7BF-46E2-A44A-6EAD6C655EEFQ34871703-B601E44E-6C17-4554-AF95-8C24261B1E3BQ34989247-42F2DEBC-2340-4281-96D7-4FE809B6951BQ35095722-D04FD991-BA4A-4215-9BC1-29B3172563AEQ35112269-456A1433-074A-4100-A6C8-5910DE93D35CQ35143457-15B33CB3-600B-49E5-A2AE-AF1EB64AE01BQ35478934-A242B949-6AD1-4AB5-8CD0-F76B6668B424Q35524687-44A640DE-5F9B-47C1-8849-708FF30C7209Q35554703-9C120A49-0177-478F-9FFE-22D91A3B7A3EQ35571053-808AA077-3DBF-4301-B50A-FE7D29C4BF74Q35690761-1FADDC06-4A0E-486F-BE9B-66CF74658431Q35743874-AE5BC79C-C9DF-45BB-8A29-5104A1C49254Q35769347-6948DF16-30F5-429E-BE45-5FCCAC10BE90Q35828638-D2BA3648-8ED5-41F0-8B0D-203DBDAFEB4EQ35848391-EA766A78-F3FE-4855-936B-E572762825B1Q35877266-EC2B516D-AC7A-4A43-A3E5-F12FFE883989Q35946619-312D5C5A-772D-453A-93FC-F923981CE52BQ36002866-5C08A7C7-2A2E-4B6D-A03D-D1726925FB96Q36125603-6708EAB9-A1F3-4B23-AE65-58B9273A258DQ36234484-DBC6752B-FF4B-423E-B591-A48EA9FAD3D8Q36447884-ED4EDE7F-3191-4049-A926-C18265CB6336Q36484688-9F844494-3707-41A4-A449-32D14AF22CF0
P2860
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@ast
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@en
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@nl
type
label
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@ast
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@en
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@nl
prefLabel
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@ast
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@en
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@nl
P2093
P50
P356
P1476
Graft-versus-tumor effects aft ...... nonmyeloablative conditioning.
@en
P2093
Ann E Woolfrey
Frédéric Baron
Mary E D Flowers
Michael B Maris
Mohamed Sorror
Razvan Diaconescu
P304
P356
10.1200/JCO.2005.08.136
P407
P577
2005-03-01T00:00:00Z